{
  "documentMetadata": {
    "title": "Parotid Swelling, Parotitis",
    "sourceFile": "Parotid Swelling, Parotitis.pdf",
    "lastUpdated": "2025-05-05"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "paragraph",
      "text": "Parotitis (swelling of the parotid gland) is caused by a variety of bacteria and viruses. Acute parotitis is most commonly due to Staph. aureus and mixed oral aerobes and/or anaerobic bacteria."
    },
    {
      "type": "list",
      "items": [
        "The distribution of potential microbial pathogens varies:",
        "Community acquired and immunocompetent differs from hospital acquired and/or immunocompromised",
        "S. aureus maybe MSSA or MRSA",
        "Suggest adding NAAT for S. aureus to culture of exudate from Stensen's"
      ]
    },
    {
      "type": "paragraph",
      "text": "Presents as either \"Hot\" tender or \"Cold\" non-tender parotid swelling:"
    },
    {
      "type": "list",
      "items": [
        "Predisposing factors: stone(s) in Stensen's duct, dehydration, poor oral hygiene, postoperative state",
        "Therapy depends on identification of specific etiologic organism.",
        "Hot/tender",
        "Cold/non-tender",
        "History/lab results may narrow differential."
      ]
    },
    {
      "type": "paragraph",
      "text": "Many serious potential complications:"
    },
    {
      "type": "list",
      "items": [
        "Extension into parapharyngeal space",
        "Lemierre's syndrome",
        "Parotid abscess",
        "Contiguous osteomyelitis of the mandible",
        "Bell's palsy"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Hot/tender:",
        "Staph. aureus: MSSA or MRSA (suggest culture and oral swab for NAAT)",
        "Strep. pyogenes",
        "Aerobic and anaerobic oral flora. Anaerobes include peptostreptococci and Fusobacterium necrophorum",
        "Aerobic gram-negative bacilli (Enterobacterales and P. aeruginosa) more likely in hospital-acquired and/or immunocompromised patients",
        "Viral",
        "Enteroviruses, Epstein-Barr virus, Mumps, HHV-6B, parainfluenza virus, EBV, CMV and rarely others (J Infect Dis 208:1979, 2013).",
        "15% positive for influenza A(H3N2) in 2014/15 influenza season in UK (Eur Surveill 20:21203, 2015).",
        "COVID-19 associated parotitis reported: Amer J Emerg Med 2021; 39:254.e3"
      ]
    },
    {
      "type": "list",
      "items": [
        "Cold/non-tender:",
        "Granulomatous disease (e.g., mycobacteria, fungi, sarcoidosis, Sjögren's syndrome)",
        "Drugs (iodides, et al.)",
        "Diabetes",
        "Cirrhosis",
        "Tumors"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Remember to get aerobic and anaerobic cultures",
        "Hot/tender, empirical therapy"
      ]
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "If MRSA is not a concern (negative NAAT) and the patient is immunocompetent:",
        "components": [
          {
            "drug": "Ampicillin-sulbactam",
            "dose": "3 gm",
            "route": "IV",
            "frequency": "q6h"
          },
          {
            "drug": "Ceftriaxone",
            "dose": "1 gm",
            "route": "IV",
            "frequency": "q24h",
            "connector": "+"
          },
          {
            "drug": "Metronidazole",
            "dose": "500 mg",
            "route": "IV",
            "frequency": "q8h",
            "connector": "or"
          },
          {
            "drug": "Clindamycin",
            "dose": "600 mg",
            "route": "IV",
            "frequency": "q6-8h"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "If MRSA is a concern (positive NAAT):",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h",
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) to one of the above regimens"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "condition": "If patient is immunocompromised:",
        "components": [
          {
            "drug": "Vancomycin",
            "dose": "15-20 mg/kg",
            "route": "IV",
            "frequency": "q8-12h",
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL)",
            "connector": "+"
          },
          {
            "drug": "Piperacillin-tazobactam",
            "dose": "4.5 gm",
            "route": "IV",
            "frequency": "(over 4 hr) q8h"
          }
        ]
      }
    },
    {
      "type": "list",
      "items": [
        "Cold/non-tender:",
        "Due to diverse possibilities need biopsy for culture for mycobacteria and fungi plus histology.",
        "No indication for empiric therapy"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Hot/tender, empirical therapy:",
        "If immunocompromised patient: Linezolid 600 mg IV/po q12h + Meropenem 1 gm IV q8h"
      ]
    },
    {
      "type": "list",
      "items": [
        "Oral therapies, if appropriate",
        "Amoxicillin-clavulanate 875/125 m po bid",
        "Moxifloxacin 400 mg po q24h",
        "If MRSA is a concern add Linezolid 600 mg po bid to either of the above. Daptomycin 10 mg/kg once daily IV is another alternative"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Duration of therapy varies depending on clinical response; usually 10-14 days"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "General overview: Am Fam Physician. 2024; 109:550."
      ]
    }
  ]
}